Loading
A phase 2 trial of TQB2102 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer is a phase 2 interventional study registered as NCT06452706 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 42 participants planned, started 2024-11-14 and due to reach its primary completion in 2026-06. Interventions recorded: TQB2102 for injection.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.